When Mallinckrodt Pharmaceuticals bought Stratatech Corp., of Madison, last August, it paid $76 million in cash for the regenerative skin tissue company, according to documents filed with federal regulators.

And there may be additional payments yet to come. The British drug company could pay up to $121 million more if certain milestones are met and royalties collected, Mallinckrodt said in the filing. That would bring the total price tag to a potential $197 million.

Read more.